menu
    • menu
    [{"orgOrder":0,"company":"KALA Bio","sponsor":"SR One","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"KPI-012","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KALA Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"","sponsorNew":"KALA Bio \/ SR One","highestDevelopmentStatusID":"8","companyTruncated":"KALA Bio \/ SR One"},{"orgOrder":0,"company":"KALA Bio","sponsor":"SR One","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"KPI-012","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KALA Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"","sponsorNew":"KALA Bio \/ SR One","highestDevelopmentStatusID":"8","companyTruncated":"KALA Bio \/ SR One"}]

    Find Clinical Drug Pipeline Developments & Deals by KALA Bio

    Menu

    KALA Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            KALA Bio

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed

                            KALA Bio

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KPI-012

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : SR One

                            Deal Size : $10.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            KALA BIO Announces $10,750,000 Private Placement

                            Details : KALA intends to use the net proceeds from the private placement to advance the clinical development of KPI-012 for the treatment of persistent corneal epithelial defect.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 30, 2024

                            Lead Product(s) : KPI-012

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : SR One

                            Deal Size : $10.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            KALA Bio

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed

                            KALA Bio

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KPI-012

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : SR One

                            Deal Size : $12.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            KALA BIO Announces $12,500,000 Private Placement

                            Details : KALA intends to use the net proceeds from the private placement to advance the clinical development of KPI-012 for the treatment of persistent corneal epithelial defect.

                            Product Name : KPI-012

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 27, 2024

                            Lead Product(s) : KPI-012

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : SR One

                            Deal Size : $12.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth